reports
Standard BioTools Announces Operational Restructuring Plan to Drive Lo...
Standard BioTools Announces Operational Restructuring Plan to Drive Long-Term Profitable Growth Company expects to achieve $45-$50 million in annualized operating expense savings in fiscal 2025Management to discuss first quarter 2024 financial results, restructuring and strategic initiatives on May 8, 2024 conference call SOUTH SAN FRANCISCO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced that it has initiated a restructuring plan to improve operational efficiency and reduce operating costs, while sup...
Standard BioTools Announces Conference Call and Webcast for First Quar...
Standard BioTools Announces Conference Call and Webcast for First Quarter 2024 Financial Results on May 8, 2024 SOUTH SAN FRANCISCO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced that it will report first quarter 2024 financial results on Wednesday, May 8, 2024, after the close of the market. The Company’s management will host a conference call and webcast at 1:30 p.m. PT, 4:30 p.m. ET, on May 8, 2024, to discuss first quarter 2024 financial results and operational progress. A press release including...
Standard BioTools Introduces New High-Throughput Multiplexed Whole Sli...
Standard BioTools Introduces New High-Throughput Multiplexed Whole Slide Imaging Modalities Set to Redefine the boundaries of Tissue Imaging New advancements, including automation, aim to fast-forward spatial biology SOUTH SAN FRANCISCO, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – today announced the introduction of new solutions that add automation and flexibility to the Imaging Mass Cytometry™ workflow on the Hyperion XTi™ Imaging System. Spatial biology is...
Standard BioTools Announces Multi-Year Strategic Engagement with Brist...
Standard BioTools Announces Multi-Year Strategic Engagement with Bristol Myers Squibb for Use of the SomaScan® Platform for Translational Medicine Research SOUTH SAN FRANCISCO, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – today announced that it has entered into a multi-year engagement with global biopharmaceutical company Bristol Myers Squibb for use of the SomaScan® Platform as a tool for clinical trials in multiple therapeutic areas through 2026. The SomaScan P...
Standard BioTools Announces Exchange of All Outstanding Series B Conve...
Standard BioTools Announces Exchange of All Outstanding Series B Convertible Preferred Stock for Common Stock SOUTH SAN FRANCISCO, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced that it has exchanged all outstanding shares of its Series B Convertible Preferred Stock (the “Series B Preferred”) for shares of common stock pursuant to an agreement with stockholders affiliated with Viking Global Investors (“Viking”) and Casdin Capital (“Casdin"). Thomas Carey, Chairman of the Standard BioTools Board of Dir...
Standard BioTools Reports Fourth Quarter and Full Year 2023 Financial ...
Standard BioTools Reports Fourth Quarter and Full Year 2023 Financial Results Achieved FY2023 core financial objectives, delivering substantial ongoing reductions in expenses and cash burn while expanding revenue and gross margins Completed merger with SomaLogic, activating strategy to build scaled leader in life sciences tools and servicesCombined pro forma revenue for FY2023 totaled $192 million and fortified balance sheet with $565 million in combined pro forma cash, cash equivalents, restricted cash and short-term investments at December 31, 20231 SOUTH SAN FRANCISCO, Calif., Feb. 28...
Standard BioTools and Next Gen Diagnostics Announce Partnership to Pro...
Standard BioTools and Next Gen Diagnostics Announce Partnership to Provide Complete Automation of Low-Cost Pathogen Sequencing SOUTH SAN FRANCISCO, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – and Next Gen Diagnostics announce the execution of a long-term agreement aimed at revolutionizing the automation of sample preparation for pathogen whole genome sequencing. Under the exclusive agreement, Standard BioTools™ will manufacture the NGD-100, a version of its microfl...
Standard BioTools to Participate in Upcoming Investor Conferences
Standard BioTools to Participate in Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – today announced that management will participate in the following investor conferences: TD Cowen’s 44th Annual Healthcare Conference on Wednesday, March 6, 2024. President and Chief Executive Officer, Michael Egholm, PhD, will present at 1:30 p.m. ET.KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on Tuesday, March 19, 2...
Standard BioTools Announces Conference Call and Webcast for Fourth Qua...
Standard BioTools Announces Conference Call and Webcast for Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024 SOUTH SAN FRANCISCO, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – today announced that it will report fourth quarter and full year 2023 financial results on Wednesday, February 28, 2024, after the close of the market. The Company’s management will host a conference call and webcast at 1:30 p.m. PT, 4:30 p.m. ET, on February 28, 2024, ...
Standard BioTools and Navignostics Announce Collaboration Agreement to...
Standard BioTools and Navignostics Announce Collaboration Agreement to Advance Imaging Capabilities in Personalized Medicine Increasing access to Imaging Mass Cytometry in pharmaceutical and clinical research settings SOUTH SAN FRANCISCO, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – today announced a collaboration agreement with Navignostics AG for development of clinical research applications and service offerings using the Hyperion XTi™ Imaging System. This c...
Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2...
Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2023 Revenue Achieving scale with pro forma full year 2023 revenue of approximately $192 million SOUTH SAN FRANCISCO, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq: LAB) (Standard BioTools or the Company), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health, today announced Standard BioTools and SomaLogic, Inc. preliminary and unaudited revenue results for the fourth quarter and full year 2023. Standard BioTools expects fourth quarter 2023 revenue of appro...
Standard BioTools Completes Merger with SomaLogic, Creating a Diversif...
Standard BioTools Completes Merger with SomaLogic, Creating a Diversified and Scaled Leader in Life Sciences Tools Establishes Leading Platform of Complementary Multi-omic Technologies with Enhanced Scale and Commercial Reach; Strengthened Balance Sheet to Self-Fund Future Growth Initiatives SOUTH SAN FRANCISCO, Calif., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq: LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health, today announced that it has completed its merger with SomaLogic, creating a leading provider of differentiated...
Standard BioTools Stockholders Approve Merger with SomaLogic
Standard BioTools Stockholders Approve Merger with SomaLogic SOUTH SAN FRANCISCO, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq: LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health, today announced that its stockholders voted to approve all proposals required to be approved in connection with the pending merger with SomaLogic (Nasdaq: SLGC) at its Special Meeting of Stockholders. “We are pleased with the outcome of today’s Special Meeting and thank our stockholders for their support for this merger,” said Michael Egholm...
Glass Lewis Recommends Standard BioTools Stockholders Vote “FOR” All P...
Glass Lewis Recommends Standard BioTools Stockholders Vote “FOR” All Proposals Relating to Proposed Merger with SomaLogic SOUTH SAN FRANCISCO, Calif., Dec. 29, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq: LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health, today announced that a second leading independent proxy advisory firm, Glass, Lewis & Co. (“Glass Lewis”), has recommended that all Standard BioTools stockholders vote “FOR” all proposals relating to the pending merger with SomaLogic at the Company’s upcoming Special Meeting of Stoc...
ISS Recommends Standard BioTools Stockholders Vote “FOR” All Proposals...
ISS Recommends Standard BioTools Stockholders Vote “FOR” All Proposals Relating to Proposed Merger with SomaLogic SOUTH SAN FRANCISCO, Calif., Dec. 22, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq: LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health - today announced that leading independent proxy advisory firm Institutional Shareholder Services (“ISS”) has recommended that Standard BioTools stockholders vote “FOR” all proposals relating to the pending merger with SomaLogic at the Company’s upcoming Special Meeting of Stockholders to be...
Standard BioTools and SomaLogic Announce Date for Special Meetings of ...
Standard BioTools and SomaLogic Announce Date for Special Meetings of Stockholders to Vote on Proposed Merger SOUTH SAN FRANCISCO, Calif. and BOULDER, Colo., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq: LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – and SomaLogic, Inc. (Nasdaq: SLGC), a leader in data-driven proteomics technology, today announced that the companies have set a date for their respective Special Meetings of Stockholders in connection with the pending all-stock merger which was previously announced on Octob...
Standard BioTools Reports Third Quarter and Year-to-Date 2023 Financia...
Standard BioTools Reports Third Quarter and Year-to-Date 2023 Financial Results Year-to-date revenue growth, gross margin expansion and operating expense reduction are testament to continued execution against financial objectivesPlanned merger with SomaLogic activates strategic M&A thesis SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- BioTools Inc. (“SBI” or the “Company”) (Nasdaq: LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today reported financial results for the third quarter ended September 30, 2023. 2023 Se...
Standard BioTools to Present at the Jefferies London Healthcare Confer...
Standard BioTools to Present at the Jefferies London Healthcare Conference SOUTH SAN FRANCISCO, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced that President and Chief Executive Officer Michael Egholm, PhD, will give a presentation with a moderated Q&A session at the Jefferies London Healthcare Conference on Wednesday, November 15 at 11:00 a.m. GMT. The presentation will be webcast live and available on the Investor Relations page of the Company’s webs...
Standard BioTools Announces Conference Call and Webcast of Third Quart...
Standard BioTools Announces Conference Call and Webcast of Third Quarter 2023 Financial Results on November 7, 2023 SOUTH SAN FRANCISCO, Calif., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced that it will report third quarter 2023 financial results on Tuesday, November 7, 2023, after the close of the market. The Company’s management will host a conference call and webcast at 1:30 p.m. PT, 4:30 p.m. ET, on November 7, 2023, to discuss third quarter 2023 f...
Standard BioTools and SomaLogic to Combine in All-Stock Merger Creatin...
Standard BioTools and SomaLogic to Combine in All-Stock Merger Creating a Diversified Leader in Life Sciences Tools Activates Standard BioTools’ strategy to unlock value in underserved portion of $100 billion industry Establishes leading platform of multi-omic technologies with the highest throughput and highest data quality to power clinical research insights Expands commercial reach with substantial cross-selling opportunities and complementary offerings Generates estimated $80 million of annual cost synergies by 2026 and enhanced combined path to profitability1 Estimated combined cas...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.